Drug intelligence / Profile preview

Lutong Capsule

Development stage: Unknown
Lead developer: Shanghai Lvgu Garden of Life Medicine
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
Administration: Oral

Overview

Lutong Capsule (颅通胶囊) is a Traditional Chinese Medicine (TCM) developed by Shanghai Green Valley Pharmaceutical Co., Ltd. for the preventive treatment of migraine. It is specifically indicated for patients presenting with the "Rheumatism and Turbidity Syndrome" (风湿化浊证) according to TCM diagnostic criteria. The drug is designed to reduce the frequency of migraine attacks and alleviate associated symptoms. It is currently undergoing clinical evaluation in China to establish its safety and efficacy profile in this patient population.

Brand names: Lutong Capsule
Other names: Lutong Jiaonang颅通胶囊

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on Lutong Capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lutong Capsule.

Explore the full profile